Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians' acceptance of practice-changing data

查看全文 作　　者：Asian Institute of Clinical Oncology(AICO)Expert [1]Panel;Louis [2]W.C.Chow

机构地区：[1]不详;[2]Organisation for Oncology and Translational Research,Unit 1604,16/F,Strand 50,50 Bonham Strand,Sheung Wan,Hong Kong SAR,China

出　　处：《Chinese Journal of Cancer Research》索引2023年第35卷第2期,共6页

摘　　要：A cross-sectional online survey was conducted.A high proportion of the Chinese breast cancer(BC)physician respondents(n=77)would prescribe extended adjuvant endocrine therapy(AET)with aromatase inhibitors(AI)beyond 5 years for postmenopausal females with BC,especially those with higher risk.Respondents with≥15 years of clinical experience were more likely to prescribe a longer duration of AET for low-risk patients.Half of the respondents considered intermittent letrozole as an acceptable option.Most respondents would prescribe adjuvant chemotherapy to genomic high-intermediate risk[Oncotype DX recurrence score(RS)21-25]females aged≤50 years regardless of the clinical risk classification. 关键词：Breast neoplasms surveys and questionnaires CHEMOTHERAPY ADJUVANT practice patterns PHYSICIANS

相关文献

参考文献（14）
引证文献（2）
耦合文献（0）

参考文献(14)

引证文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Adjuvant therapy for hormone receptor-positive breast cancer: Perspective from a survey on breast cancer physicians' acceptance of practice-changing data

参考文献(14)

引证文献(2)

用户提示